Outset Medical, Inc. Stock Price, News & Analysis

Outset Medical, Inc. (Nasdaq: OM), a leader in medical technology, will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference on March 8, 2022, at 11:50 AM PT. This event will provide insights into their groundbreaking Tablo Hemodialysis System, designed to simplify dialysis and reduce costs. A live and archived webcast will be available on the Outset Medical website. Tablo allows for dialysis to be administered easily across various settings, transforming patient care and operational efficiency.

Outset Medical, Inc. (Nasdaq: OM) reported record annual revenue of $102.6 million for 2021, marking a 105.5% year-over-year growth. The fourth quarter revenue reached $28.2 million, up 63.2% from the previous year. The company achieved a gross margin of 11.8% in Q4, improving significantly from 2.4% in Q4 2020. Operating expenses for 2021 were $138.1 million, with a net loss of ($131.9 million). Looking ahead, Outset projects revenue for 2022 between $142 million and $150 million, indicating further growth.

Outset Medical, Inc. (Nasdaq: OM) announced management participation in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 18, 2022, at 12:40pm PT / 3:40pm ET. The event will be accessible via a live and archived webcast on Outset's website. Outset Medical is revolutionizing dialysis with its Tablo Hemodialysis System, which simplifies treatment and reduces costs. This FDA-cleared technology enables delivery of dialysis anywhere by utilizing integrated water purification and on-demand dialysate production.

Outset Medical, Inc. (Nasdaq: OM) will announce its financial results for Q4 and the full year of 2021 after market close on February 16, 2022. A conference call will follow at 2:00 PM PT (5:00 PM ET), led by CEO Leslie Trigg and CFO Nabeel Ahmed. The call can be accessed by dialing specific numbers for domestic and international callers. Outset's Tablo® Hemodialysis System aims to simplify dialysis with its innovative technology, making treatment accessible and efficient across various settings.

Outset Medical, Inc. (NASDAQ: OM) has received FDA clearance for a new sterilization method of the Tablo Hemodialysis System cartridge. This advancement allows production to shift to North America, particularly Mexico, which is expected to reduce costs and enhance supply chain reliability. The new method is eco-friendly, utilizing e-beam technology. CEO Leslie Trigg highlighted that this milestone aims to improve gross margins while addressing manufacturing challenges and logistics.

Outset Medical, Inc. (NASDAQ: OM) has been named in Fast Company’s inaugural Next Big Things in Tech list, recognizing its groundbreaking Tablo® Hemodialysis System.

This innovative dialysis solution simplifies treatment and reduces costs, making it easier for patients and providers. Tablo combines advanced features like wireless connectivity and integrated water purification into a single unit. CEO Leslie Trigg emphasizes the importance of consumer-centric design in improving the dialysis experience. This recognition reflects Outset's commitment to revolutionizing dialysis care.

Outset Medical reported Q3 2021 net revenue of $26.3 million, a 91.3% increase from $13.8 million in Q3 2020. The gross margin improved to 11.2%, up from (37.3%) year-over-year. Full year 2021 revenue guidance was raised to $99 million to $101 million, indicating 98% to 102% growth over 2020. The company recorded a net loss of ($30.5 million), or ($0.65) per share, significantly better than the previous year’s loss. Cash stood at $406.4 million as of September 30, 2021.

Outset Medical, Inc. (Nasdaq: OM) announced management's participation in a fireside chat at the Stifel 2021 Virtual Health Care Conference on November 16, 2021, at 1:40 PM PT. The event will be available via a live and archived webcast on Outset's Investors section. Outset Medical is revolutionizing dialysis with the Tablo Hemodialysis System, making it easier and more cost-effective for patients and providers. This innovative technology enables dialysis to be administered anywhere, incorporating advanced data analytics and operational simplicity.